ÁñÁ«ÊÓƵ

This phase 1 randomized study assesses the safety and tolerability of zerlasiran, a short interfering RNA targeting hepatic synthesis of apolipoprotein(a), and its effects on serum concentrations of lipoprotein(a), in healthy participants and patients with stable atherosclerotic cardiovascular disease.

This prespecified analysis of the Cholesterol Lowering via Bempedoic Acid, an ATP Citrate Lyase (ACL)–Inhibiting Regimen (CLEAR) Outcomes trial investigates if bempedoic acid is associated with a reduction in the total burden of cardiovascular events in patients at high risk for cardiovascular disease.

This 32-country randomized clinical trial assesses the effects of bempedoic acid on cardiovascular outcomes in statin-intolerant patients receiving bempedoic acid vs placebo for primary prevention of a first major adverse cardiovascular event.

This study examines the appropriateness of artificial intelligence model responses to fundamental cardiovascular disease prevention questions.

This cross-sectional study analyzes county-level eligibility, participation, adherence, and completion rates for cardiac rehabilitation services among Medicare beneficiaries.

This phase 1 study evaluated the safety and tolerability of 4 different doses of a short interfering RNA designed to reduce hepatic production of apolipoprotein(a) and assessed associated changes in plasma concentrations of lipoprotein(a), compared with placebo, among individuals with elevated lipoprotein(a) levels and no known cardiovascular disease.

This quality improvement study describes representation of women within leadership committees of clinical trials and in lead authorship positions of ensuing cardiovascular trial publications.

This secondary analysis of the randomized clinical ACCELERATE trial examines whether lipoprotein(a)-associated cardiovascular risk is modulated by systemic inflammation in optimally treated patients at high risk for cardiovascular disease.

This cohort study investigates whether exercise and clinical variables have differential associations with mortality outcomes in men and women and assesses whether sex-specific risk scores better estimate all-cause mortality among patients undergoing treadmill testing.

This randomized clinical trial compares the effects of evolocumab vs placebo on change in percent atheroma volume among adult patients with angiographic coronary disease despite treatment with statins.